Brief: Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma
30/03/2026 14:09
March 30 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 COMBINATION STUDY OF IDE849, DLL3 TOP1 ADC, AND IDE161, PARG INHIBITOR, IN DLL3 UPREGULATED SOLID TUMOR INDICATIONS, INCLUDING SCLC, NETS, NECS, AND MELANOMA IDEAYA BIOSCIENCES INC - TARGETS CLINICAL DATA UPDATE FOR IDE849 AND IDE161 IN H2 2026 Source text: ID:nPn2gvj4Wa Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj